The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas
Open Access
- 23 December 2015
- journal article
- review article
- Published by Bioscientifica in Journal of Endocrinology
- Vol. 228 (3) , R73-R83
Abstract
Prolactinomas are the most frequently observed pituitary adenomas and most of them respond well to conventional treatment with dopamine agonists (DAs). However, a subset of prolactinomas fails to respond to such therapies and is considered as DA-resistant prolactinomas (DARPs). New therapeutic approaches are necessary for these tumors. Transforming growth factor β1 (TGFβ1) is a known inhibitor of lactotroph cell proliferation and prolactin secretion, and it partly mediates dopamine inhibitory action. TGFβ1 is secreted to the extracellular matrix as an inactive latent complex, and its bioavailability is tightly regulated by different components of the TGFβ1 system including latent binding proteins, local activators (thrombospondin-1, matrix metalloproteases, integrins, among others), and TGFβ receptors. Pituitary TGFβ1 activity and the expression of different components of the TGFβ1 system are regulated by dopamine and estradiol. Prolactinomas (animal models and humans) present reduced TGFβ1 activity as well as reduced expression of several components of the TGFβ1 system. Therefore, restoration of TGFβ1 inhibitory activity represents a novel therapeutic approach to bypass dopamine action in DARPs. The aim of this review is to summarize the large literature supporting TGFβ1 important role as a local modulator of pituitary lactotroph function and to provide recent evidence of the restoration of TGFβ1 activity as an effective treatment in experimental prolactinomas.Keywords
This publication has 115 references indexed in Scilit:
- Matrix‐dependent perturbation of TGFβ signaling and diseaseFEBS Letters, 2012
- Temozolomide in the management of dopamine agonist–resistant prolactinomasClinical Endocrinology, 2012
- Molecular Basis for the Regulation of Angiogenesis by Thrombospondin-1 and -2Cold Spring Harbor Perspectives in Medicine, 2012
- Active and Total Transforming Growth Factor-β1 Are Differentially Regulated by Dopamine and Estradiol in the PituitaryEndocrinology, 2011
- Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT statusEuropean Journal of Clinical Investigation, 2011
- Perturbation of transforming growth factor (TGF)-ß1 association with latent TGF-β binding protein yields inflammation and tumorsProceedings of the National Academy of Sciences, 2008
- Changes in thrombospondin-1 levels in the endothelial cells of the anterior pituitary during estrogen-induced prolactin-secreting pituitary tumorsJournal of Endocrinology, 2006
- Estrogens sensitize anterior pituitary gland to apoptosisAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Smad-dependent and Smad-independent pathways in TGF-β family signallingNature, 2003
- Type beta transforming growth factor (TGF-β) is a potent stimulator of the basal secretion of follicle stimulating hormone (FSH) in a pituitary monolayer systemBiochemical and Biophysical Research Communications, 1986